Vantage logo

First blood: Rubius approaches its big test

The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…

Vantage logo

A ternary outcome for Tocagen

Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.